巨细胞病毒所致大泡性角膜病变患者行后弹力层剥除自动角膜内皮移植术后局部更昔洛韦治疗
这项前瞻性非对照病例系列研究纳入6例(6眼)巨细胞病毒角膜内皮炎所致内皮失代偿患者,行后弹力层剥除自动角膜内皮移植术(DSAEK)后持续局部使用0.5%更昔洛韦(GCV)每日4至6次。术后未检测到巨细胞病毒角膜内皮炎复发,最佳矫正视力(BCVA)从术前平均1.52±0.68 LogMAR显著改善至术后1年0.15±0.16 LogMAR(P<0.01),眼压控制良好,未观察到与长期局部GCV相关的不良反应。
要点
- 6眼DSAEK术后持续局部0.5% GCV每日4至6次,未检测到CMV角膜内皮炎复发。
- BCVA从术前平均1.52±0.68 LogMAR改善至术后1年0.15±0.16 LogMAR(P<0.01)。
- 术后眼压均控制在10-20 mm Hg,未观察到与长期局部GCV相关的不良反应。
核心结论
- 持续局部应用0.5% GCV对预防CMV角膜内皮炎复发有效,并在DSAEK术后为CMV角膜内皮炎患者提供了良好的中期临床结局。
研究设计与样本
- 前瞻性非对照病例系列研究,纳入6例(6眼)因CMV角膜内皮炎导致内皮失代偿并接受DSAEK的患者。
- 术后持续局部使用0.5% GCV,每日4至6次。
- 平均随访40个月(范围12-60个月)。
主要发现
- DSAEK术后未检测到CMV角膜内皮炎复发。
- 平均术前BCVA为1.52±0.68 LogMAR(范围0.52-2.40 LogMAR),术后1年显著改善至0.15±0.16 LogMAR(范围-0.08至0.30 LogMAR),P<0.01。
- 所有患者术后眼压均控制良好(10-20 mm Hg)。
- 平均术前供体ECD为2692±177 cells/mm2,术后6、12、36个月平均ECD分别为1974、1771、1174 cells/mm2,对应ECD损失分别为26%、33%、54%。
- 未观察到与长期局部GCV相关的不良反应。
关键数值与推荐
- 局部使用0.5% GCV,每日4至6次,持续给药。
- 术后1年BCVA平均0.15±0.16 LogMAR,较术前平均1.52±0.68 LogMAR改善,P<0.01。
- 术后6、12、36个月ECD损失分别为26%、33%、54%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: To investigate the efficacy of topical ganciclovir (GCV) for preventing disease recurrence and improving the surgical outcome post-Descemet's stripping automated endothelial keratoplasty (DSAEK) in patients with cytomegalovirus (CMV) endotheliitis. METHODS: This prospective, non-comparative case series study involved six eyes of six patients with endothelial decompensation due to CMV endotheliitis who underwent DSAEK, followed by a continuous, four to six times daily, topical administration of 0.5% GCV. Patient demographics, clinical history, and preoperative and postoperative examination (including any recurrence of CMV endotheliitis post-DSAEK), best corrected visual acuity (BCVA), intraocular pressure (IOP), graft survival rate and endothelial cell density (ECD) were examined. RESULTS: No recurrence of CMV endotheliitis was detected post-DSAEK. The mean follow-up period was 40 months (range, 12-60 months). The mean preoperative BCVA was 1.52±0.68 LogMAR (range, 0.52-2.40 LogMAR), yet it had significantly improved to 0.15±0.16 LogMAR (range: -0.08 to 0.30 LogMAR) by 1 year postoperative (P<0.01). In all patients, IOP was well controlled (10-20 mm Hg) postsurgery. The mean preoperative donor ECD was 2692±177 cells/mm2, and the mean postoperative ECD was 1974, 1771 and 1174 cells/mm2 for the ECD loss of 26%, 33% and 54% at 6, 12 and 36 months, respectively. No adverse effects were observed associated with the long-term topical administration of GCV. CONCLUSION: The continuous topical application of 0.5% GCV was found to be effective for preventing the recurrence of CMV endotheliitis, and it provided the optimal mid-term clinical outcomes post-DSAEK in patients with CMV endotheliitis. TRIAL REGISTRATION NUMBER: UMIN000026746.
引用
- Kitazawa K, Jongkhajornpong P, Inatomi T, et al. Topical ganciclovir treatment post-Descemet's stripping automated endothelial keratoplasty for patients with bullous keratopathy induced by cytomegalovirus. Br J Ophthalmol. 2018. PMID: 29363530. doi:10.1136/bjophthalmol-2017-311145
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。